Symptom Based Treatment Affects Brain Plasticity - Cognitive Training in Patients With Affective Symptoms (APIC-II)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03183947 |
|
Recruitment Status :
Completed
First Posted : June 12, 2017
Last Update Posted : December 10, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Depression Schizophrenia | Procedure: fMRI Behavioral: Neurofeedback Other: PANAS Other: BDI-II Other: ERQ | Not Applicable |
The ability to regulate emotions is a central element of mental health that is significantly affected in various psychiatric disorders. Its importance for development and maintenance of depressive symptomatology has been widely shown; e.g. patients with depression have a significantly reduced ability to regulate emotions in response to negative stimuli. However, emotion regulation abilities may pose as an important resilience factor that can counteract the development of depressive symptoms. The loss of the ability to regulate emotions is not only observed in depression, but is also a core factor in negative symptoms of schizophrenia.
Cognitive reappraisal training is an established method to improve emotion regulation. The cognitive reappraisal of a stimulus or situation works by reinterpreting the emotional stimulus or situation and can change the course of the emotional response. Over the last years this form of cognitive reappraisal training has become a standard approach in the treatment of affective disorders.
The prefrontal cortex (PFC) plays an important role in emotion regulation. In line with this it has been shown that patients with reduced emotion regulation ability display impaired functioning of the PFC. Aim of the study is to train patients to consciously upregulate activity in the PFC and thereby to increase emotion regulation ability. On the behavioral level this is expected to correlate with a reduced experience of negative mood. In order to regulate the PFC, participants are instructed to use cognitive reappraisal strategies. Cognitive reappraisal is an effective and well-investigated strategy to improve emotion regulation and is a standard cognitive-behavioral psychotherapeutic intervention. During cognitive reappraisal the meaning of a picture is reinterpreted in order to reduce the emotional reaction. Recent fMRI studies have shown that cognitive reappraisal is associated with an increase in prefrontal activity and a decrease of amygdala activation.
The new technique of real-time fMRI enables subjects to influence their brain activity in certain areas based on neurofeedback. Ongoing brain activity as measured by fMRI is reported to the participants in real time via brain computer interface (BCI). In order to influence brain activity, mental strategies are usually recommended to the participants that have been shown to increase activity in the respective area. Due to the identification of contingency between feedback and mental strategies participants are able to control their own brain activity consciously. It has been shown that psychiatric symptomatology can be improved using this non-invasive technique. In the current study it will be investigated whether neurofeedback of the PFC has a positive influence on affective symptoms in patients with depression and schizophrenia, respectively. In detail it is researched whether the upregulation of activity in the PFC can lead to an increase in subjective well-being. Two groups of patients (depression (N=40) and schizophrenia (N=40)) as well as a group of healthy participants will receive neurofeedback-training of the PFC. Aim of the study is an improvement of depressive (or negative) symptoms as well as the investigation of the impact of neurofeedback on resting-state networks in the brain.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 81 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Symptom Based Treatment Affects Brain Plasticity - Cognitive Training in Patients With Affective Symptoms |
| Actual Study Start Date : | August 29, 2017 |
| Actual Primary Completion Date : | December 6, 2019 |
| Actual Study Completion Date : | December 6, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: fMRI Neurofeedback regulation of left PFC
Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
|
Procedure: fMRI
collection of functional brain data for 1 hour per day
Other Name: functional magnetic resonance imaging Behavioral: Neurofeedback Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 & 4; controls: Days 2 & 3) Other: PANAS to assess the mood before and after the fMRI and after 4 weeks during a telephone interview
Other Name: Positive And Negative Affect Scales Other: BDI-II to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview
Other Name: Beck's depression inventory Other: ERQ To assess emotion regulation strategies before and after neurofeedback training (patients: day 3&4; controls: day 2&3) and after 4 weeks during a telephone interview
Other Name: Emotion regulation questionnaire |
|
Experimental: fMRI Neurofeedback of right PFC
Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
|
Procedure: fMRI
collection of functional brain data for 1 hour per day
Other Name: functional magnetic resonance imaging Behavioral: Neurofeedback Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 & 4; controls: Days 2 & 3) Other: PANAS to assess the mood before and after the fMRI and after 4 weeks during a telephone interview
Other Name: Positive And Negative Affect Scales Other: BDI-II to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview
Other Name: Beck's depression inventory Other: ERQ To assess emotion regulation strategies before and after neurofeedback training (patients: day 3&4; controls: day 2&3) and after 4 weeks during a telephone interview
Other Name: Emotion regulation questionnaire |
- change in self-control over neuronal activity in PFC [ Time Frame: 1 week ]fMRI-BCI as a measure before and after the regulation of the brain activity
- Changes from baseline in brain plasticity [ Time Frame: 2 weeks ]fMRI as a measure for brain plasticity before and after neurofeedback
- Change in pathology (depression) [ Time Frame: 4 weeks after interventions ]BDI-II as a measure of the intensity and quality of depressive symptoms before training and 4 weeks following the intervention
- specificity of left or right PFC neurofeedback [ Time Frame: 2 weeks ]
- change in resting state brain activation [ Time Frame: 2 weeks ]Resting state fMRI as a measure before and after neurofeedback
- Change in pathology (mood) [ Time Frame: 4 weeks after interventions ]Positive And Negative Affect Scales (PANAS) as a measure of mood before and after the fMRI and after 4 weeks during a telephone interview
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Depression according to ICD-10 (F32.x, F33.x, F31.3 or F34.x); Schizophrenia according to ICD-10 (F2x); or healthy subjects
- Fluent German language skills
Exclusion Criteria:
- any contraindication to MRI examination or claustrophobia
- pregnant or lactating women
- acute suicidal tendency
- persons incapable of giving consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03183947
| Germany | |
| University Hospital RWTH Aachen, Department of Psychiatry, Psychotherapy and Psychosomatics | |
| Aachen, Germany, 52074 | |
| Principal Investigator: | Klaus Mathiak, Prof MD PhD | University Hospital RWTH Aachen, Department of Psychiatry, Psychotherapy and Psychosomatics |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | RWTH Aachen University |
| ClinicalTrials.gov Identifier: | NCT03183947 |
| Other Study ID Numbers: |
17-094 |
| First Posted: | June 12, 2017 Key Record Dates |
| Last Update Posted: | December 10, 2019 |
| Last Verified: | December 2019 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
fMRI neurofeedback emotion regulation |
schizophrenia cognitive reappraisal depression |
|
Depression Schizophrenia Affective Symptoms |
Behavioral Symptoms Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders |